Venture capital deals

May 20, 2013

Karyopharm Therapeutics Inc., a Natick, Mass.-based developer of nuclear transport modulators, has raised $48.2 million in Series B funding. Delphi Ventures was joined by an undisclosed “private investor.” www.Karyopharm.com

Effector Therapeutics, a San Diego-based developer of small molecule selective translation regulators for cancer, has raised $45 million in Series A funding. Backers include U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage University Partners and Mission Bay Capital. www.effector.com

Alteryx Inc., an Irvine, Calif.-based provider of strategic analytics, has raised $12 million in new VC funding from Toba Capital and return backer SAP Ventures. www.alteryx.com

Zyme Solutions, a Redwood Shores, Calif.-based provider of channel data management solutions, has raised $5 million in new VC funding from Susquehanna Growth Equitywww.zymesolutions.com

Sign up for Dan's daily email newsletter on deals and deal-makers: GetTermSheet.com

FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.

Quotes delayed at least 15 minutes. Market data provided by Interactive Data. ETF and Mutual Fund data provided by Morningstar, Inc. Dow Jones Terms & Conditions: http://www.djindexes.com/mdsidx/html/tandc/indexestandcs.html. S&P Index data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions